Unlearn Stock

unlearn.aiHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $85.17MM

Unlearn.AI is an AI healthcare company specializing in creating digital twins of patients to conduct clinical studies. Their technology aims to estimate the effects of therapy options for those affected by disease. Unlearn.AI was founded in 2017 by Charles Fisher Ph.D., Jonathan Walsh Ph.D., Aaron Smith Ph.D., and Graham Siegel JD and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Unlearn, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Unlearn’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Unlearn.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Charles Fisher Ph.D
Co-Founder, Chief Executive Officer, President & Board Member
Dave Miller
Chief Science Officer
Jonathan Walsh Ph.D
Co-Founder & Head of Data Science
Aaron Smith Ph.D
Co-Founder, Head of Machine Learning & Board Member

Board Members

Alaa Halawa
Mubadala Capital-Ventures
Dylan Morris Ph.D
Insight Partners
Francisco Gimenez Ph.D
John Hamer Ph.D

Frequently Asked Questions About Unlearn’s Stock

Can you buy Unlearn stock?
Unlearn is not publicly traded on NYSE or NASDAQ in the U.S. To buy Unlearn stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Unlearn stock?
Yes, you can sell stock of a private company like Unlearn. Forge can help you sell your Unlearn stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Unlearn’s stock price?
Unlearn is a privately held company and therefore does not have a public stock price. However, you may access Unlearn’s private market stock price with Forge Data.
What is Unlearn’s stock ticker symbol?
Unlearn does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Biotech AI startup Unlearn adds $15 mln and OpenAI CTO to board
Unlearn.AI, which has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate regulatory approval, the company told Reuters on Tuesday.
A Perk to Getting These Jobs: You Pick Your Pay
Unlearn, which uses artificial intelligence to speed clinical trials, recently began offering new hires multiple pay options. It’s among a growing number of companies that let new hires customize their compensation with different combinations of salary, equity and, in some cases, benefits.
How ‘digital twins’ could change the way we develop new drugs
Now, using machine learning and generative AI, a startup called Unlearn.ai is aiming to transform clinical trials by tackling one of its biggest challenges: recruiting enough people to participate. Its solution? Digital twins.
Updated on: Dec 1, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.